Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
Pulmatrix Inc +2.33% Pre
Pulmatrix Inc PULM | 1.32 1.32 | +2.33% 0.00% Pre |
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the lungs by inhalation to treat migraine and respiratory diseases
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ Technology
